LYVE1 anticorps (AA 24-228)
Aperçu rapide pour LYVE1 anticorps (AA 24-228) (ABIN115688)
Antigène
Voir toutes LYVE1 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- AA 24-228
-
Specificité
- This antibody detetcs Lyve-1.
-
Réactivité croisée (Details)
- Species reactivity (tested):Mouse. This antibody is not reactive with Human LYVE-1.
-
Purification
- Protein G Chromatography (+ his tag depletetion)
-
Immunogène
- Highly pure recombinant Mouse soluble LYVE-1 produced in insect cells. This recombinant soluble LYVE-1 consists of amino acid 24 (Ala) to 228 (Gly) and is fused to a C-terminal His-tag (6xHis).
-
-
-
-
Indications d'application
-
ELISA (1-15 μg/mL). Western blot (1-2 μg/mL). FACS analysis (3-20 μg/mL). Immunohistochemistry on Frozen Sections (1-5 μg/mL). For formalin-fixed, paraffin-embedded sections use the immunogen affinity purifiedantibody ABIN115689.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Reconstitution
- Restore in sterile water/PBS to a concentration of > 0.5 mg/mL.
-
Buffer
- PBS, pH 7.2 without preservatives or stabilizers
-
Agent conservateur
- Without preservative
-
Conseil sur la manipulation
- Avoid repeated freezing and thawing.
-
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- The lyophilized IgG is stable at 2-8 °C for one month and at -20 °C for longer. When reconstituted the antibody is stable for at least six weeks at 2-8 °C. For longer store in aliquots at -20 °C.
-
-
-
: "Long-Lasting Impact of Neonatal Exposure to Total Body Gamma Radiation on Secondary Lymphoid Organ Structure and Function." dans: Radiation research, Vol. 184, Issue 4, pp. 352-66, (2015) (PubMed).
: "Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis." dans: The American journal of pathology, Vol. 176, Issue 4, pp. 1950-8, (2010) (PubMed).
: "Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo." dans: Circulation, Vol. 119, Issue 2, pp. 281-9, (2009) (PubMed).
-
-
- LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))
-
Autre désignation
- LYVE-1
-
Sujet
- LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41 % similar to the CD44 HA receptor with a 212- esidue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 Molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE- molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymphspecific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.Synonyms: CRSBP-1, CRSBP1, Cell surface retention sequence-binding protein 1, Extracellular link domain-containing protein 1, HAR, Hyaluronic acid receptor, LYVE1, Lymphatic vessel endothelial hyaluronic acid receptor 1, XLKD1
-
ID gène
- 114332
-
NCBI Accession
- NP_444477
-
UniProt
- Q8BHC0
-
Pathways
- Glycosaminoglycan Metabolic Process
Antigène
-